Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container.
Due to the ASA component, AGGRENOX is also contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug products and in patients with the syndrome of asthma, rhinitis and nasal polyps.
Patients with rare hereditary problems of fructose intolerance and/or galactose intolerance (e.g. galactosaemia) should not take this medicine. AGGRENOX contains approximately 23 mg sucrose and 106 mg of lactose per maximum recommended daily dose.
Alcohol Warning
Patients who consume three or more alcoholic drinks every day should be counselled about the bleeding risks involved with chronic, heavy alcohol use while taking AGGRENOX, due to the ASA component.
If a patient is to undergo elective surgery, consideration should be given to discontinue AGGRENOX 10 days prior to surgery to allow for the reversal of the effect.
Bleeding
As any antiplatelet agents, which cause bleeding, the use of AGGRENOX may increase the risk of bleeding such as skin haemorrhage, gastrointestinal bleeding and intracerebral haemorrhage. The addition of other antiplatelet agents (e.g. Clopidogrel, Ticlopidine) to AGGRENOX may further increase the risk of serious bleeding. Even though no study has been conducted, such combination is not recommended.
Due to the ASA component, the concomitant use of AGGRENOX with either selective serotonin reuptake inhibitors (SSRIs) or corticosteroids can increase the gastrointestinal bleeding.
This product contains 106 mg of lactose and 22.5 mg sucrose per maximum recommended daily dose. Patients with rare hereditary problems of fructose intolerance and/or galactose intolerance e.g. galactosaemia should not take this medicine.
|
